Home Biosimilar Antibodies Immunology & Inflammation CD markers inhibitor Monalizumab (Anti-Human CD159a) For research use only.
Not for use in humans.

Monalizumab (Anti-Human CD159a)

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

Monalizumab (Anti-Human CD159a)

Click to purchase the isotype control of Monalizumab (Anti-Human CD159a)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 10.7mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective CD markers Inhibitors

Biological Activity

Description Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.

Product Details

CAS No. 1228763-95-8
Molecular Weight 150 kDa
Isotype Human IgG4-Kappa
Application Monalizumab (Anti-Human CD159a)
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Monalizumab (Anti-Human CD159a) | Monalizumab (Anti-Human CD159a) supplier | purchase Monalizumab (Anti-Human CD159a) | Monalizumab (Anti-Human CD159a) cost | Monalizumab (Anti-Human CD159a) manufacturer | order Monalizumab (Anti-Human CD159a) | Monalizumab (Anti-Human CD159a) distributor